Neuland to open peptide facility this summer

India’s Neuland Laboratories has announced that it will open the first of four planned modules at the new peptide facility at its Bonthapally site. This will add commercial-scale capabilities up to multi-tonne to the existing clinical-stage S-Block facilities. 

Module One will provide 6,370 L of solid- and liquid-phase peptide synthesis (SPPS/LPPS) reactor capacity for sizes of 250-3,000 L in LPPS, plus SPPS reactors at up to 500 L scale. The company said that it has secured firm commitments of about $30 million. 

“With GLP-1 manufacturing consuming a growing share of global peptide capacity, Neuland is targeting innovator and emerging biotech programmes facing tightening access to clinical and commercial manufacturing across a broad range of indications,” the company said.

The site has been designed for ongoing expansion, with space to accommodate additional 2,000 L SPPS synthesisers and multiple 5,000 L LPPS reactors as future modules come online. Neuland expects R&D employee numbers to grow by >10% this year and the  manufacturing team to more than double to support the ramp‑up. 

The facility includes expanded downstream capabilities, such as commercial-scale multi‑column prep‑HPLC systems, lyophilisers and dryers sized, enhanced solvent‑handling and tank‑farm infrastructure, dedicated warehouses and upgraded waste‑management systems. The plants will also feature digital operation systems and scalable peptide technologies across synthesis, purification and drying.